To functionally investigate the involvement of deregulated S1P metabolism in amyloid pathology along with strategies to counter AD pathogenesis, we applied a drug repositioning approach by treating amyloidogenic APP/PS1 mice with fingolimod (FTY720), an FDA-approved drug for the use in the relapsing‐remitting form of multiple sclerosis54. Here, APP is linked to Alzheimer disease.